Last reviewed · How we verify
AScVS + Prazosin
AScVS is an autologous stem cell vaccine that stimulates immune responses against cancer, combined with prazosin, an alpha-1 adrenergic antagonist that may enhance immune function.
AScVS is an autologous stem cell vaccine that stimulates immune responses against cancer, combined with prazosin, an alpha-1 adrenergic antagonist that may enhance immune function. Used for Advanced or metastatic solid tumors (Phase 3 indication under investigation).
At a glance
| Generic name | AScVS + Prazosin |
|---|---|
| Also known as | AScVS (Haffkine), T. Prazosin (sun pharma) |
| Sponsor | Haffkine Bio-Pharmaceutical Corporation Ltd. |
| Drug class | Cancer immunotherapy vaccine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AScVS (Autologous Stem Cell Vaccine System) is designed to activate the patient's own immune system to recognize and attack cancer cells. Prazosin, an alpha-1 blocker traditionally used for hypertension, is hypothesized to potentiate immune responses by modulating adrenergic signaling. The combination aims to improve anti-tumor immunity through dual mechanisms.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 indication under investigation)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Hypotension (from prazosin component)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AScVS + Prazosin CI brief — competitive landscape report
- AScVS + Prazosin updates RSS · CI watch RSS
- Haffkine Bio-Pharmaceutical Corporation Ltd. portfolio CI